Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study-Reference-Cited by-同舟云学术

Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study

Published:2024-02 Issue: Volume:68 Page:102426
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Forbes Anna K.,Hinton William,Feher Michael D.,Elson William,Joy Mark,Ordóñez-Mena José M.,Fan Xuejuan,Cole Nicholas I.,Banerjee Debasish,Suckling Rebecca J.,de Lusignan Simon,Swift Pauline A.^ORCID

Publisher

Elsevier BV

Reference32 articles.

1. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy;Perkovic;N Engl J Med,2019

2. Dapagliflozin in patients with chronic kidney disease;Heerspink;N Engl J Med,2020

3. Empagliflozin in patients with chronic kidney disease;Herrington;N Engl J Med,2023

4. UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease;Herrington,2022

5. UK kidney association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease;Herrington,2023

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Early Clinical Experience of Finerenone in People with Chronic Kidney Disease and Type 2 Diabetes in Japan—A Multi-Cohort Study from the FOUNTAIN (FinerenOne mUltidatabase NeTwork for Evidence generAtIoN) Platform;Journal of Clinical Medicine;2024-08-28

2. Chronic kidney disease: detect, diagnose, disclose—a UK primary care perspective of barriers and enablers to effective kidney care;BMC Medicine;2024-08-15

3. Enhancing clinical service design for multimorbidity management: A comprehensive approach to joined‐up care for diabetes, chronic kidney disease, and heart failure;Diabetic Medicine;2024-07-08

4. Kidneys and Blood Pressure: A Key Link;EMJ Nephrology;2024-07-04

5. La definición del síndrome cardiovascular-reno-metabólico (cardiovascular-kidney-metabolic syndrome) y su papel en la prevención, estatificación del riesgo y tratamiento. Una oportunidad para la Nefrología;Nefrología;2024-05